Search Results for "data"
Search again or select article below to purchase. Single article price: $45. Order 3 or more at one time and receive a 10% discount.
Sort by relevance | Sort by date
Searched for data. Results 331 to 340 of 1113 total matches.

In Brief: Casgevy for Beta Thalassemia

   
The Medical Letter on Drugs and Therapeutics • May 13, 2024  (Issue 1702)
-arm trial (CLIMB THAL-111) in 52 patients (only 35 had sufficient follow-up data) 12 to 35 years 1 ...
Exagamglogene autotemcel (Casgevy – Vertex), a cell-based gene therapy recently approved for treatment of sickle cell disease1, has now been approved by the FDA for treatment of patients ≥12 years old with transfusion-dependent beta thalassemia. Casgevy is the first gene therapy that uses CRISPR/Cas9 gene-editing technology to be approved in the US for any disorder. Betibeglogene autotemcel (Zynteglo), an autologous lentiviral vector cell-based gene therapy, was approved in the US in 2022 for treatment of transfusion-dependent beta thalassemia.
Med Lett Drugs Ther. 2024 May 13;66(1702):79   doi:10.58347/tml.2024.1702d |  Show IntroductionHide Introduction

In Brief: Doxycycline for STI Post-Exposure Prophylaxis

   
The Medical Letter on Drugs and Therapeutics • Jul 22, 2024  (Issue 1707)
STUDIES — Issuance of the new recommendation was based on data from three randomized, open-label trials ...
The CDC has issued a recommendation for use of a single dose of doxycycline for post-exposure prophylaxis (PEP) of bacterial sexually transmitted infections (STIs), specifically syphilis, chlamydia, and gonorrhea, in men who have sex with men (MSM) and transgender women (TGW) who had a bacterial STI within the previous 12 months.
Med Lett Drugs Ther. 2024 Jul 22;66(1707):119-20   doi:10.58347/tml.2024.1707f |  Show IntroductionHide Introduction

Revakinagene Taroretcel (Encelto) – A Gene Therapy for Idiopathic Macular Telangiectasia (online only)

   
The Medical Letter on Drugs and Therapeutics • Apr 28, 2025  (Issue 1727)
24 months was significantly lower with Encelto than with sham treatment in both trials. Data beyond ...
Revakinagene taroretcel-lwey (Encelto – Neurotech), an intravitreal allogeneic cell-based gene therapy, has been approved by the FDA for treatment of idiopathic macular telangiectasia type 2 in adults. It is the first treatment to be approved in the US for this indication.
Med Lett Drugs Ther. 2025 Apr 28;67(1727):e74   doi:10.58347/tml.2025.1727f |  Show IntroductionHide Introduction

Adult Immunization

   
The Medical Letter on Drugs and Therapeutics • Oct 17, 2022  (Issue 1661)
inactivated influenza vaccine is recommended. 4. For PCV15 or PCV20, no data are available. For PPSV23 ...
The Advisory Committee on Immunization Practices (ACIP) recommends use of certain vaccines in adults residing in the US. Routine childhood immunization has reduced the overall incidence of some of these vaccine-preventable diseases, but many adults remain susceptible. Recommendations for vaccination against COVID-19, seasonal influenza, and monkeypox and vaccination of travelers have been reviewed separately.
Med Lett Drugs Ther. 2022 Oct 17;64(1661):161-8 |  Show IntroductionHide Introduction

Safe Needles

   
The Medical Letter on Drugs and Therapeutics • Apr 05, 1991  (Issue 841)
blunting mechanisms might decrease transmission of infection by accidental needlestick, but no data ...
Accidental needlesticks can lead to infection with hepatitis viruses, human immunodeficiency virus, and other blood-borne bacterial, viral, and fungal pathogens (DK Henderson et al, Ann Intern Med, 113:740, 1990). Re-capping used needles is the most frequent cause of needlestick injuries (J Jagger et al, N Engl J Med, 319:284, 1988; MH Becker et al, Am J Infect Control, 18:232, 1990).
Med Lett Drugs Ther. 1991 Apr 5;33(841):32 |  Show IntroductionHide Introduction

Masoprocol for Multiple Actinic Keratoses

   
The Medical Letter on Drugs and Therapeutics • Oct 15, 1993  (Issue 907)
may be effective for topical treatment of multiple actinic keratoses, but published data are sparse. A controlled ...
Masoprocol cream 10% (meso-nordihydroguiaretic acid, Actinex - Reed and Carnrick) is now available in the USA for topical treatment of actinic keratoses.
Med Lett Drugs Ther. 1993 Oct 15;35(907):97-8 |  Show IntroductionHide Introduction

The Female Condom

   
The Medical Letter on Drugs and Therapeutics • Dec 24, 1993  (Issue 912)
COPYRIGHT LAWS CONCLUSION — The new female condom, judging from the limited data available, appears ...
A condom for women (Reality - Wisconsin Pharmacal) to prevent pregnancy and sexually transmitted diseases, including AIDS, has been approved for marketing by the US Food and Drug Administration (FDA). Already available in many family planning clinics, it will be available in pharmacies in a few months.
Med Lett Drugs Ther. 1993 Dec 24;35(912):123-4 |  Show IntroductionHide Introduction

Vinorelbine For Treatment of Advanced Non-Small-Cell Lung Cancer

   
The Medical Letter on Drugs and Therapeutics • Aug 18, 1995  (Issue 955)
% and a median survival of 40 weeks (T Le Chevalier et al, J Clin Oncol, 12:360, 1994). Preliminary data ...
Vinorelbine (Navelbine - Burroughs Wellcome), a semisynthetic vinca alkaloid, has been approved by the US Food and Drug Administration for parenteral use in the treatment of advanced non-small-cell lung cancer (NSCLC). Various combinations of cisplatin (Platinol), vinblastine (Velban, and others), mitomycin (Mutamycin), ifosfamide (Ifex), etoposide (VePesid) and paclitaxel (Taxol) have been used previously for this indication.
Med Lett Drugs Ther. 1995 Aug 18;37(955):72-3 |  Show IntroductionHide Introduction

Topotecan Hydrochloride for Metastatic Ovarian Cancer

   
The Medical Letter on Drugs and Therapeutics • Oct 25, 1996  (Issue 986)
OF U.S. AND INTERNATIONAL COPYRIGHT LAWS CONCLUSION — Although published data are limited, topotecan ...
Topotecan hydrochloride (Hycamtin - SmithKline Beecham) was recently approved by the U.S. Food and Drug Administration for parenteral use as a single agent in patients with metastatic ovarian cancer refractory to other drugs. Initial treatment for metastatic ovarian cancer usually consists of cisplatin (Platinol) or carboplatin (Paraplatin) plus paclitaxel (Taxol) or cyclophosphamide (Cytoxan, and others).
Med Lett Drugs Ther. 1996 Oct 25;38(986):96-7 |  Show IntroductionHide Introduction

Gliadel Wafers for Treatment of Brain Tumors

   
The Medical Letter on Drugs and Therapeutics • Sep 11, 1998  (Issue 1035)
implantation of the Gliadel wafers are unknown, but animal data obtained with similar polymer implants indicate ...
A biodegradable polymer 'wafer' (Gliadel - Rh ne-Poulenc Rorer) impregnated with the alkylating agent carmustine (BCNU; Bicnu) has been marketed in the USA for local treatment of recurrent glioblastoma multiforme that requires re-operation. The dime-sized polyanhydride wafers are implanted into the surgical cavity left behind after resection. Release of the alkylating agent directly into the area of the tumor bypasses the blood-brain barrier (H Brem and R Langer, Sci Med, 3:1, 1996).
Med Lett Drugs Ther. 1998 Sep 11;40(1035):92 |  Show IntroductionHide Introduction